IL-17, IL-23 and IL-12/23 biologics on every 2026 New York Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in New York cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | HealthSpring Assurance Rx$35.70/moS5617-013 | Wellcare Value Script$42.40/moS4802-138 | Wellcare Classic$45.70/moS4802-077 | HealthSpring Extra Rx$91.60/moS5617-353 | AARP Medicare Rx Saver from UHC$105.80/moS5921-379 | SilverScript Choice$116.00/moS5601-006 | Humana Basic Rx Plan$140.90/moS5884-216 | Humana Value Rx Plan$158.90/moS5884-218 | AARP Medicare Rx Preferred from UHC$163.70/moS5921-382 | Humana Premier Rx Plan$173.60/moS5884-217 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stelaraustekinumab | Tier 5PA25%QL 0.5/28d | Not covered | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA25%QL 0.5/28d | Tier 5PA25%QL 1.5/84d | Tier 5PA26%QL 1.5/84d | Not covered | Tier 5PA33%QL 1.5/84d |
| ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and others | Tier 5PA25%QL 0.5/28d | Not covered | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA25%QL 0.5/28d | Tier 5PA25%QL 1.5/84d | Tier 5PA26%QL 1.5/84d | Not covered | Tier 5PA33%QL 1.5/84d |
| Wezlanaustekinumab-auub | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Selarsdiustekinumab-aekn | Tier 3PA25%QL 0.5/28d | Not covered | Not covered | Tier 3PA17%QL 0.5/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Skyrizirisankizumab | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 1/28d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 2/84d | Tier 5PA26%QL 2/84d | Tier 5PA31%QL 1/28d | Tier 5PA33%QL 2/84d |
| Tremfyaguselkumab | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Tier 5PA25% | Tier 5PA25%QL 1/28d | Tier 5PA25%QL 3/84d | Tier 5PA26%QL 3/84d | Tier 5PA31% | Tier 5PA33%QL 3/84d |
| Cosentyxsecukinumab | Tier 5PA25%QL 10/28d | Tier 5PA25%QL 10/28d | Tier 5PA25%QL 10/28d | Tier 5PA25%QL 10/28d | Tier 5PA25%QL 10/30d | Not covered | Tier 5PA25%QL 8/28d | Tier 5PA26%QL 8/28d | Tier 5PA31%QL 10/30d | Tier 5PA33%QL 8/28d |
| Taltzixekizumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Bimzelxbimekizumab | Not covered | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 4/28d | Not covered | Not covered | Not covered | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.